Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visceral leishmaniasis in paediatrics.

Dimitris A Kafetzis1, Helen C Maltezou

  • 1University of Athens Second Department of Pediatrics, P. and A. Kyriakou Children's Hospital, Athens, Greece. kafetzis@ath.forthnet.gr

Current Opinion in Infectious Diseases
|May 17, 2002
PubMed
Summary

Visceral leishmaniasis (VL) is a severe parasitic disease. Miltefosine offers a promising, affordable oral treatment option for VL, potentially improving patient outcomes globally.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Public health and clinical implications of multidrug-resistant shigellosis cases in a reception centre for refugees/migrants, Greece, October-December 2019.

European journal of public health·2020
Same author

Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys.

BMC research notes·2012
Same author

Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.

Antimicrobial agents and chemotherapy·2012
Same author

Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg+/HBeAg- mothers.

Cellular & molecular immunology·2010
Same author

Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis.

Pediatric pulmonology·2010
Same author

Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers.

Clinical and vaccine immunology : CVI·2010

Area of Science:

  • Tropical medicine
  • Infectious diseases
  • Parasitology

Background:

  • Visceral leishmaniasis (VL) is a serious vector-borne disease affecting 500,000 people annually.
  • Diagnosis often requires parasite demonstration in tissue, despite promising molecular methods.
  • Current treatments like antimonials and amphotericin B have limitations in efficacy, cost, or administration.

Purpose of the Study:

  • To evaluate miltefosine as a potential new treatment for visceral leishmaniasis.
  • To assess its efficacy, safety, and ease of administration for global health applications.

Main Methods:

  • Review of recent studies on miltefosine's use in visceral leishmaniasis.
  • Analysis of clinical trial data regarding efficacy and safety profiles.

Related Experiment Videos

  • Consideration of miltefosine's pharmacokinetic and pharmacodynamic properties.

    • Main Results:

    • Miltefosine has demonstrated significant efficacy as an oral treatment for VL.
    • It is generally well-tolerated, with a favorable safety profile compared to existing therapies.
    • Its oral administration simplifies treatment delivery, especially in resource-limited settings.

    Conclusions:

    • Miltefosine represents a significant advancement in visceral leishmaniasis treatment.
    • It offers a safe, effective, and affordable oral alternative, potentially transforming patient care.
    • Further research and wider implementation are warranted to combat this neglected tropical disease.